Lijuan Y. Chen

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Correction: A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

Correction: A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

Journal: Frontiers in immunology

Published: February 16, 2026

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Journal: Lancet (London, England)

Published: June 11, 2025

Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer.

Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer.

Journal: Journal for immunotherapy of cancer

Published: April 24, 2025

First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis.

First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis.

Journal: Frontiers in oncology

Published: November 22, 2024

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

Journal: Frontiers in immunology

Published: September 07, 2024

Good response of cadonilimab (PD-1/CTLA-4 bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: A case report.

Good response of cadonilimab (PD-1/CTLA-4 bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: A case report.

Journal: Asian journal of surgery

Published: February 17, 2024

Sulforaphane inhibits the migration and invasion of BPDE-induced lung adenocarcinoma cells by regulating NLRP12.

Sulforaphane inhibits the migration and invasion of BPDE-induced lung adenocarcinoma cells by regulating NLRP12.

Journal: Toxicology and applied pharmacology

Published: January 24, 2024

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy.

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy.

Journal: Journal for immunotherapy of cancer

Published: June 16, 2023

Calreticulin (CALR)-induced activation of NF-ĸB signaling pathway boosts lung cancer cell proliferation.

Calreticulin (CALR)-induced activation of NF-ĸB signaling pathway boosts lung cancer cell proliferation.

Journal: Bioengineered

Published: March 10, 2022

Efficacy of nilotinib in the first-line treatment of chronic myeloid leukemia and the analysis of factors affecting molecular responses

Efficacy of nilotinib in the first-line treatment of chronic myeloid leukemia and the analysis of factors affecting molecular responses

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: July 14, 2020

TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma.

TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma.

Journal: Aging

Published: April 20, 2020

Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1.

Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1.

Journal: Cell death & disease

Published: February 17, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026